1. Academic Validation
  2. 2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014)

2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014)

  • Expert Opin Ther Pat. 2016;26(2):149-73. doi: 10.1517/13543776.2016.1118059.
Alberto Leoni 1 Alessandra Locatelli 1 Rita Morigi 1 Mirella Rambaldi 1
Affiliations

Affiliation

  • 1 a Dipartimento di Farmacia e Biotecnologie , Università degli Studi di Bologna , Bologna , Italy.
Abstract

Introduction: 2-Indolinone is a well-known aromatic heterocyclic organic compound. A lot of work has been done on this bicyclic structure by academic and company researchers to synthesize compounds directed to a plethora of molecular targets in order to discover new drug leads. This review presents up-to-date information in the field of Cancer therapy research based on this small building block.

Areas covered: The present review gives an account of the recent patent literature (2008-2014) describing the discovery of 2-indolinone derivatives with selected therapeutic activities. In this period, a large amount of patents were published on this topic. We have limited the analysis to 37 patents on 2-indolinone derivatives having potential clinical application as chemotherapeutic agents. In this review, the therapeutic applications of 2-indolinone derivatives for the treatment of Cancer reported in international patents have been discussed.

Expert opinion: 2-Indolinone is the scaffold of the compounds considered from a medicinal chemistry perspective. Many of them have been developed and marketed for therapeutic use. In Cancer chemotherapy, progress has been made in designing selective 2-indolinone derivatives. Some of them show preclinical efficacy. However, 2-indolinone has not exhausted all of its potential in the development of new compounds for clinical applications and remains a great tool for future research.

Keywords

2-indolinone; Inhibitor; histone deacetylase; mouse double minute 2; oxindole; polo-like kinase; tyrosine kinase inhibitors.

Figures
Products